Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor

@article{Abrams2009RivaroxabanAN,
  title={Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor},
  author={Paris Abrams and Christopher R. Emerson},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2009},
  volume={29}
}
Thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke often result in long‐term disability and/or mortality. The anticoagulants currently available have been effective in the treatment and prevention of these disorders; however, parenteral administration, variable pharmacokinetics and pharmacodynamics, drug and dietary interactions, and a requirement for frequent monitoring of efficacy and safety limit use of these drugs. Rivaroxaban is a… Expand
52 Citations
Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor.
  • 16
  • Highly Influenced
  • PDF
Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
  • 7
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice
  • 8
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 66 REFERENCES
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases
  • A. Turpie
  • Medicine
  • Arteriosclerosis, thrombosis, and vascular biology
  • 2007
  • 205
  • PDF
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases
  • 105
New oral anticoagulants in atrial fibrillation.
  • 191
  • PDF
A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement
  • 297
  • PDF
...
1
2
3
4
5
...